PharmTech Drug Digest 11.20
News|Articles|August 15, 2017

Catalent Applied Drug Delivery Institute Appoints Jim Spavins to Advisory Board

Catalent Applied Drug Delivery Institute (CADDI) announced that Jim Spavins, a veteran pharmaceutical industry executive, has joined the institute’s advisory board.

On July 26, 2017, Catalent Applied Drug Delivery Institute (CADDI) announced that Jim Spavins, a veteran pharmaceutical industry executive, has joined the institute’s advisory board. Founded by Catalent, a global drug development, delivery, and supply partner, CADDI specializes in facilitating research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

“I look forward to working with the CADDI board to help rapidly advance innovative drug delivery solutions to patients,” said Spavins, in a company press release. “There has never been a more exciting time to leverage astonishing scientific advances in disease understanding with optimum delivery technology.”

With more than 36 years of industry and academic experience, Spavins has worked at all levels of research and development, reaching the position of senior vice-president of Pfizer’s Global Pharma Therapeutics Pharmaceutical Sciences group before starting his own consulting business, Spavins Consulting.

Source: Catalent Applied Drug Delivery Institute


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.